002099 海翔药业
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.530-1.790-6.147-7.1721.440
总资产报酬率 ROA (%)0.368-1.232-4.411-5.2791.072
投入资产回报率 ROIC (%)0.407-1.368-4.895-5.8431.177

边际利润分析
销售毛利率 (%)27.14224.44026.73814.02726.636
营业利润率 (%)5.233-4.301-17.341-21.3754.046
息税前利润/营业总收入 (%)9.840-4.291-20.477-22.908-0.062
净利润/营业总收入 (%)5.407-5.039-17.224-19.4113.183

收益指标分析
经营活动净收益/利润总额(%)-31.67343.455-23.51734.630226.024
价值变动净收益/利润总额(%)256.787-48.5862.28825.229-41.999
营业外收支净额/利润总额(%)2.5054.8340.2190.425-8.527

偿债能力分析
流动比率 (X)1.2011.2781.2971.4531.647
速动比率 (X)0.7150.8710.9381.0651.088
资产负债率 (%)30.00931.39631.17225.51027.263
带息债务/全部投入资本 (%)21.39922.37621.95615.74317.308
股东权益/带息债务 (%)360.586341.054348.943524.765464.876
股东权益/负债合计 (%)233.661218.894221.110292.245266.936
利息保障倍数 (X)2.200-18.8016.60915.8870.016

营运能力分析
应收账款周转天数 (天)81.54481.57578.31376.54465.768
存货周转天数 (天)239.442217.856190.371173.972182.408